EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study

Pichatorn Suppakitjanusant, Yuhan Ji, Mary O Stevenson, Panicha Chantrapanichkul, R Craig Sineath, Michael Goodman, Jessica A Alvarez, Vin Tangpricha

Journal of Clinical & Translational Endocrinology · 2020-09 · 21 · 100230

DOI: 10.1016/j.jcte.2020.100230 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Clinical & Translational Endocrinology, 2020-09. Verfasst von Pichatorn Suppakitjanusant und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Many transgender people take hormone therapy to affirm their gender identity. One potential long-term consequence of gender affirming hormone therapy is increased body mass index (BMI), which may be associated with metabolic syndrome, cardiovascular disease and higher mortality. Only a few published studies explored changes in BMI in transgender people taking gender affirming hormone therapy (GAHT). OBJECTIVE: To examine the changes in BMI longitudinally in response to GAHT in transgender women and men. METHODS: We conducted a retrospective cohort study of transgender individuals who received GAHT from the endocrinology clinic between January 1, 2000 and September 6, 2018. Subjects who sought GAHT were included if they had two separate measurements of BMI and were excluded if they had a BMI greater than 35 kg/m2 or were missing demographic data at entry. We used a linear mixed model to analyze the longitudinal change in BMI. RESULTS: There were a total of 227 subjects included in this cohort. Among subjects already on GAHT, transgender women were receiving GAHT longer than transgender men (6.59 ± 9.35 vs 3.67 ± 3.43 years, p-value = 0.04). Over the period of 7 years, there was a significant increase in BMI in transwomen who newly initiated GAHT (p-value 0.004). There were no changes in BMI in transgender men and women already on GAHT or in transgender men who newly initiated GAHT in the study. CONCLUSION: We conclude that BMI significantly increases in transwomen but not in transmen after initiation of GAHT in a single center based in the United States. In transwomen and transmen, BMI appears to be stable following 3 to 6 years of GAHT. Future investigations should examine the causes for increased BMI in transgender women including type of GAHT, diet and lifestyle, and association with risk of metabolic syndrome and cardiovascular disease.

Schlagwörter

Stichwörter der Autor:innen

Body mass indexGender affirming hormone therapyTransgender

Autor:innen und Institutionen

  • Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
  • Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Emory University, Atlanta, GA, United States.
  • Division of Gynecologic Endocrinology, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Urology, Oregon Health & Science University, Portland, OR, United States.
  • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.

Förderung

  • National Institutes of Health
  • National Center for Advancing Translational Sciences
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Suppakitjanusant, P., Ji, Y., Stevenson, M. O., Chantrapanichkul, P., Sineath, R. C., Goodman, M., Alvarez, J. A., & Tangpricha, V. (2020). Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study. Journal of Clinical & Translational Endocrinology, 21, 100230. https://doi.org/10.1016/j.jcte.2020.100230

Vancouver

Suppakitjanusant P, Ji Y, Stevenson MO, Chantrapanichkul P, Sineath RC, Goodman M, et al. Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study. Journal of Clinical & Translational Endocrinology. 2020;21:100230. doi:10.1016/j.jcte.2020.100230

BibTeX
@article{Suppakitjanusant2020,
  author = {Suppakitjanusant, Pichatorn and Ji, Yuhan and Stevenson, Mary O and Chantrapanichkul, Panicha and Sineath, R Craig and Goodman, Michael and Alvarez, Jessica A and Tangpricha, Vin},
  title = {Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study},
  journal = {Journal of Clinical & Translational Endocrinology},
  year = {2020},
  volume = {21},
  pages = {100230},
  doi = {10.1016/j.jcte.2020.100230}
}
Kostenlos starten →